S. Karger AG

SHERPA: Unknown

People

  1. Clarkson
    Clarkson
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Salles
    Salles
  5. Giralt
    Giralt
  6. Mauro
    Mauro
  7. Horwitz
    Horwitz
  8. Palomba
    Palomba
  9. Rampal
    Rampal
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (107)
  2. Hematologic Malignancies, Division of (107)
  3. Center for Hematologic Malignancies (80)
  4. Adult Leukemia (29)
  5. Lymphoma (25)
  6. GSK Faculty (19)
  7. Sloan Kettering Institute Faculty (17)
  8. Executive Committee, Center for Hematologic Malignancies (16)
  9. Bone Marrow Transplant (12)
  10. Molecular Pharmacology and Chemistry Program Faculty (11)
Search Within
  1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (77)
  2. Journal Article (30)
Groups
  1. Department of Medicine (107)
  2. Hematologic Malignancies, Division of (107)
  3. Center for Hematologic Malignancies (80)
  4. Adult Leukemia (29)
  5. Lymphoma (25)
  6. GSK Faculty (19)

More Groups

People
  1. Bayard Clarkson (10)
  2. Andrew Zelenetz (8)
  3. Jens Atzodien (8)
  4. Matthew Matasar (8)
  5. Subhash Gulati (8)
  6. Gilles Salles (7)

More People

Years
  1. 2025 (1)
  2. 2024 (8)
  3. 2023 (17)
  4. 2022 (13)
  5. 2021 (7)
  6. 2020 (7)

More Years

Publications
  1. Oncology Research and Treatment (71)
  2. Acta Haematologica (23)
  3. Oncology (3)
  4. Experimental Cell Biology (2)
  5. Onkologie (2)
  6. Cytogenetic and Genome Research (1)

More Publications

Results (107)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety of extended pirtobrutinib exposure in relapsed and/or refractory B-cell malignancies
    Journal Article

    Roeker, L. E.; Coombs, C. C.; Shah, N. N.; Jurczak, W.; Woyach, J. A.; Cheah, C. Y.; Patel, K.; Maddocks, K.; Wang, Y.; Zinzani, P. L.; more...
    Acta Haematologica (2025)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel (ide-cel) versus standard (std) regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): Updated analysis from KarMMa-3
    Meeting Abstract

    Scheid, C.; Rodriguez-Otero, P.; Ailawadhi, S.; Arnulf, B.; Patel, K.; Cavo, M.; Nooka, A. K.; Manier, S.; Callander, N.; Costa, L. J.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel (ide-cel) vs standard regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): A KarMMa-3 analysis in high-risk subgroups
    Meeting Abstract

    Raab, M. S.; Patel, K.; Rodríguez-Otero, P.; Manier, S.; Baz, R.; Cavo, M.; Callander, N.; Costa, L. J.; Moreau, P.; Solomon, S. R.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel (ide-cel) versus standard regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): A KarMMa-3 analysis in the modified intent-to-treat (mITT) population
    Meeting Abstract

    Scheid, C.; Manier, S.; Ailawadhi, S.; Rodríguez-Otero, P.; Arnulf, B.; Patel, K.; Solomon, S. R.; Baz, R.; Jagannath, S.; Raje, N.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • TRANSCEND FL: Phase 2 study results of lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL)
    Meeting Abstract

    Borchmann, P.; Morschhauser, F.; Dahiya, S.; Palomba, M. L.; García-Sancho, A. M.; Ortega, J. L. R.; Kuruvilla, J.; Jäger, U.; Cartron, G.; Izutsu, K.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Efficacy of pirtobrutinib in BTK-inhibitor pre-treated relapsed/refractory CLL/SLL: Phase 1/2 BRUIN study results by prior BCL2-inhibitor therapy
    Meeting Abstract

    Woyach, J. A.; Brown, J. R.; Ghia, P.; Roeker, L. E.; Patel, K.; Eyre, T. A.; Munir, T.; Lech-Maranda, E.; Lamanna, N.; Tam, C. S.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients with prior cBTKi: Updated safety and efficacy including high-risk subgroup analyses from the phase 1/2 BRUIN study
    Meeting Abstract

    Cohen, J. B.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Cheah, C. Y.; Eyre, T. A.; Ujjani, C. S.; Koh, Y.; Kim, W. S.; Nasta, S. D.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Pirtobrutinib in heavily pre-treated richter transformation: Updated efficacy and safety results with 18-month median survival follow-up from the phase 1/2 BRUIN study
    Meeting Abstract

    Wierda, W. G.; Shah, N. N.; Cheah, C. Y.; Lewis, D.; Hoffman, M. S.; Coombs, C. C.; Lamanna, N.; Shuo, M. A.; Jagadeesh, D.; Munir, T.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Acute febrile neutrophilic dermatosis (sweet syndrome) in acute myeloid leukemia patients: A 28-year institutional experience
    Journal Article

    Cowen, E. A.; Barrios, D. M.; Pulitzer, M. P.; Moy, A. P.; Dusza, S. W.; De Wolf, S.; Geyer, M. B.; Markova, A.
    Acta Haematologica (2024)

    Fulltext@MSK | Save
  • Primary overall survival (OS) analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in relapsed/refractory large B-cell lymphoma (R/R LBCL)
    Meeting Abstract

    Dreger, P.; Westin, J.; Oluwole, O.; Kersten, M. J.; Miklos, D.; Perales, M. A.; Ghobadi, A.; Rapoport, A.; Sureda, A.; Jacobson, C.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save